[Federal Register Volume 68, Number 43 (Wednesday, March 5, 2003)]
[Notices]
[Pages 10483-10484]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-5075]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on March 18, 2003, from 
10:30 a.m. to 12:45 p.m.
    Location: Food and Drug Administration, 5515 Security Lane, 
conference room A on the 11th floor, suite 1113, Rockville, MD. This 
meeting will be held by a telephone conference call. The public is 
welcome to attend the open portion of the meeting at the location in 
the first sentence of this paragraph. A speaker phone will be provided 
at the specified location.
    Contact Person: Jody G. Sachs or Denise H. Royster, Food and Drug 
Administration, Center for Biologics Evaluation and Research (HFM-71), 
301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-
8138 (301-443-0572 in the Washington, DC area), code 12391. Please call 
the Information Line for up-to-date information on this meeting.
    Agenda: The committee will review and discuss the selection of 
strains to be included in the influenza virus vaccine for the 2003-2004 
season.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by March 12, 
2003. Oral presentations from the public will be scheduled between 
approximately 11:30 a.m. to 12:30 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before March 12, 2003, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and

[[Page 10484]]

an indication of the approximate time requested to make their 
presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Jody G. Sachs or 
Denise H. Royster at least 7 days in advance of the meeting.
    FDA regrets that it was unable to publish this notice 15 days prior 
to the March 18, 2003, Vaccines and Related Biological Products 
Advisory Committee meeting. Because the agency believes there is some 
urgency to bring this issue to public discussion and qualified members 
of the Vaccines and Related Biological Products Advisory Committee were 
available at this time, the Commissioner of Food and Drugs concluded 
that it was in the public interest to hold this meeting even if there 
was not sufficient time for the customary 15-day public notice.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: February 26, 2003.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 03-5075 Filed 3-4-03; 8:45 am]
BILLING CODE 4160-01-S